Form 4: Aardvark Therapeutics CEO Tien-Li Lee Reports Beneficial Ownership Changes After IPO
SEC Form 4 Filing
Following Aardvark Therapeutics' IPO, CEO Tien-Li Lee reports changes in beneficial ownership, including the conversion of Series A Convertible Preferred Stock into common stock.
Summary
- On February 14, 2025, Tien-Li Lee, CEO of Aardvark Therapeutics, reported changes in beneficial ownership of the company's stock.
- The transactions include the conversion of 41,303 shares of Series A Convertible Preferred Stock into common stock.
- Lee also acquired 16,542 shares of common stock at a price of $16 per share.
- Following these transactions, Lee directly owns 1,496,175 shares of common stock and indirectly owns 1,474,028 shares through a spouse.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing related to insider transactions following an IPO. It doesn't contain any particularly positive or negative information, but transparency is generally viewed favorably.
Industry Context
This Form 4 filing is a standard requirement following an IPO, as it discloses changes in beneficial ownership by company insiders. It provides transparency to investors regarding the holdings and transactions of key individuals like the CEO.
Stakeholder Impact
- Shareholders are informed about the CEO's holdings and recent transactions.
- The filing provides transparency regarding insider activity, which can influence investor confidence.
Key Dates
| Date | Description |
|---|---|
| 02/14/2025 | Date of the reported transactions, including conversion of preferred stock and purchase of common stock. |
| 02/19/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.